EP
FULC icon

Essential Partners’s Fulcrum Therapeutics FULC Stock Holding History

Essential Partners’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.98K Buy
814
+813
+81,300% +$4.95K ﹤0.01% 1797
2026
Q1 		$8 Hold
1
– – ﹤0.01% 2843
2025
Q4 		$11 Hold
1
– – ﹤0.01% 2749
2025
Q3 		$9 Buy
+1
New +$7 ﹤0.01% 2659

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Essential Partners's FULC Position: Q2 2026 in Review

Essential Partners increased its Fulcrum Therapeutics (FULC) stake by 81,300% in Q2 2026, buying an estimated $4.95K and bringing the position to 814 shares worth $2.98K. The position accounts for ﹤0.01% of the portfolio, ranked #1797.

Essential Partners first reported a position in FULC in Q3 2025 and has held it in 4 quarters since. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Essential Partners held 814 shares of Fulcrum Therapeutics worth $2.98K as of Q2 2026.
  • Essential Partners bought 813 Fulcrum Therapeutics shares in Q2 2026, an estimated $4.95K.
  • Fulcrum Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1797 holding.
  • Essential Partners first reported a position in Fulcrum Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.